Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Aberrant retinal structure and vasculature in mouse models of dominant retinopathies caused by CRX homeodomain mutations.

Scientific reports·2026

Same author

Clinical Outcomes and Predictors of Retinal Breaks in Patients With Vitreous Hemorrhage Secondary to a Posterior Vitreous Detachment.

Journal of vitreoretinal diseases·2026

Same author

Corrigendum to "Oculomics and AI: The eye as a biomarker for health span" [Asia-Pac J Ophthalmol 15 (1) (2026) 100282].

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026

Same author

RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.

Investigative ophthalmology & visual science·2026

Same author

Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.

Expert opinion on biological therapy·2026

Same author

Lipemia Retinalis as a Masquerader of Multiple Myeloma.

Retina (Philadelphia, Pa.)·2026

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Intravitreal Injections in the Ovine Eye

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Intravitreal pharmacotherapy: applications in retinal disease.

Anita G Prasad¹, Ramin Schadlu, Rajendra S Apte

¹Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA.

Comprehensive Ophthalmology Update

|January 19, 2008

Summary

Intravitreal pharmacotherapies are increasingly used for retinal diseases like diabetic macular edema. While effective, potential complications such as cataracts and glaucoma require careful management and monitoring.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jul 8, 2026

Intravitreal Injections in the Ovine Eye

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Area of Science:

Ophthalmology
Retinal Diseases
Pharmacotherapy

Background:

Intravitreal pharmacotherapies are frequently employed for various retinal conditions.
Indications span choroidal neovascularization, diabetic macular edema, and neoplastic processes.

Purpose of the Study:

To review current and emerging intravitreal pharmacotherapies for retinal diseases.
To discuss the benefits and complications associated with these treatments.
To guide practitioners in maximizing therapeutic benefits while minimizing ocular and systemic risks.

Main Methods:

Review of current literature on intravitreal pharmacotherapies.
Analysis of indications, efficacy, and complications.
Discussion of new pharmacologic agents and systemic medication applications.

Main Results:

Intravitreal injections are indicated for a range of retinal diseases.
Common complications include cataract formation, glaucoma, and endophthalmitis.
New agents and systemic drug applications expand treatment possibilities.

Conclusions:

Intravitreal pharmacotherapy offers expanded treatment options for retinal diseases.
Careful consideration of benefits versus risks, including potential complications, is essential.
Emerging data will refine therapeutic strategies for optimal patient outcomes.